Invivyd, Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals

Other Names/Subsidiaries

  • Adagio Therapeutics
See more in Biomedtracker

Latest on Invivyd, Inc.

Scrip

Invivyd Moves On From Adintrevimab While Monitoring For New COVID-19 Variants

 
• By Joseph Haas

Adjusting to a SARS-CoV-2 virus that is mutating even more quickly than many biopharma companies expected, Adagio Therapeutics, Inc. has undergone a name change to Invivyd Inc., reduced headcount an

Scrip

Finance Watch: With Limited Fundraising Options, Biotechs Restructure To Extend Cash Runways

 
• By Mandy Jackson

Bogged down by an ongoing spat with its largest shareholder and a share price that continues to flirt with penny stock territory, Mereo BioPharma Group plc announced an updated operating plan on 18

Scrip

Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid

 
• By Scrip Team

Pfizer’s Bourla Suggests Second Paxlovid Course For Relapse; FDA Isn’t Having It In response to reports of some patients taking Pfizer Inc. ’s COVID-19 treatment, Paxlovid (nirmatrelvir and ritonavir

Scrip

Can Adagio’s Adintrevimab Hold Up Against Omicron BA.2?

 
• By Alaric DeArment

Adagio Therapeutics, Inc. plans to seek an emergency use authorization (EUA) for the monoclonal antibody ADG20 (adintrevimab) for COVID-19 as Phase II/III data have shown it effective at preventing a